Browse our anti-Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) Antibodies

Full name:
anti-Non-Muscle Myosin Heavy Polypeptide 9 Antibodies (MYH9)
On are 108 Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) Antibodies from 18 different suppliers available. Additionally we are shipping Non-Muscle Myosin Heavy Polypeptide 9 Kits (20) and Non-Muscle Myosin Heavy Polypeptide 9 Proteins (7) and many more products for this protein. A total of 142 Non-Muscle Myosin Heavy Polypeptide 9 products are currently listed.
BDPLT6, C80049, D0Jmb2, dfna17, E030044M24Rik, epsts, fi22c04, Fltn, ftns, KLG/PTK7, MHA, myh9, myh9l2, Myhn-1, Myhn1, myosin, nmhc-ii-a, NMHC II-A, NMHCIIA, NMMHC, NMMHC-A, NMMHC-IIA, nmmhca, NMMHC II-a, non-muscle, nonmuscle, TU72.6, wu:fi22c04, wu:fj85e11, zgc:66164, zgc:162029

Most Popular Reactivities for anti-Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) Antibodies

Select your species and application

anti-Human Antibodies:

anti-Rat (Rattus) Antibodies:

anti-Mouse (Murine) Antibodies:

All available anti-Non-Muscle Myosin Heavy Polypeptide 9 Antibodies

Go to our pre-filtered search.

Top referenced anti-Non-Muscle Myosin Heavy Polypeptide 9 Antibodies

  1. Dog (Canine) Polyclonal MYH9 Primary Antibody for ICC, IF - ABIN153126 : Klingner, Cherian, Fels, Diesinger, Aufschnaiter, Maghelli, Keil, Beck, Tolić-Nørrelykke, Bathe, Wedlich-Soldner: Isotropic actomyosin dynamics promote organization of the apical cell cortex in epithelial cells. in The Journal of cell biology 2014 (PubMed)

  2. Dog (Canine) Polyclonal MYH9 Primary Antibody for WB - ABIN2783216 : Sabbir, Dillon, Mowat: Dlc1 interaction with non-muscle myosin heavy chain II-A (Myh9) and Rac1 activation. in Biology open 2016 (PubMed)

More Antibodies against Non-Muscle Myosin Heavy Polypeptide 9 Interaction Partners

Human Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) interaction partners

  1. Heterozygous deletional mutation (c.5803delG) in exon 41 of the MYH9 gene is associated with inherited thrombocytopenia.

  2. cytokinesis failure in megakaryocytes is the consequence of both the absence of NMIIB and a low RhoA activity that impairs NMIIA localization at the cleavage furrow through increased actin turnover.

  3. The loss of junctional NMIIA, upon Coronin 1B (show CORO1B Antibodies) knockdown, perturbed RhoA (show RHOA Antibodies) signaling.

  4. Results identified nonsynonymous variants in MYH9 and ABCA4 (show ABCA4 Antibodies) to be the most frequent risk loci in nonsyndromic orofacial clefts in the Taiwanese population.

  5. Our study is the first to identify genetic predisposition to transplant renal artery stenosis in patients with MYH9 risk allelic variants (rs4821480, rs4821481, rs3752462, rs11089788, rs136211, rs5756168, rs2032487, and rs2239784)

  6. The hearing impairment associated with MYH9 disorder in this family was characterized as adult onset, progressive, and high-frequency dominant. Hematological manifestations of MYH9 disorder show complete penetrance, whereas extra-hematological manifestations show incomplete penetrance and variable expressivity in this family.

  7. mass spectrum followed by immunoprecipitation identified non-muscle myosin heavy chain-IIA (NMMHC-IIA) as the CXCR4 (show CXCR4 Antibodies)-interacting protein. Furthermore, pharmaceutical inhibition of NMMHC-IIA by blebbistatin dampened the nuclear translocation of CXCR4 (show CXCR4 Antibodies) as well as the metastatic capacity of RCC (show XRCC1 Antibodies) cells

  8. The rs3752462 polymorphism of MYH9 is associated with high systolic blood pressure in patients with CKD. The T allele in the dominant model was associated with an elevated risk for high systolic blood pressure .

  9. The Raf (show RAF1 Antibodies)-ERK1/2 (show MAPK1/3 Antibodies) signaling pathway is involved in regulation of NMIIA by DT-13.

  10. HhnRNP-K-mediated regulation of NMHC IIA mRNA translation contributes to the control of enucleation in erythropoiesis.

Xenopus laevis Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) interaction partners

  1. Data show that the locomotion and blebbing of the primordial germ cells (PGCs) required F-actin, myosin II activity and RhoA/Rho-associated protein kinase (ROCK) signaling.

Mouse (Murine) Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) interaction partners

  1. Data show that deletion of myosin heavy chain II-A (Myh9)/myosin heavy chain II-B (Myh10 (show MYH10 Antibodies)) caused severe hydroureter/hydronephrosis at birth.

  2. our data indicated that PGDHC is a Pg-derived, cell-permeable ceramide that possesses a unique property of promoting osteoclastogenesis via interaction with Myh9 which, in turn, activates a Rac1/DC-STAMP (show TM7SF4 Antibodies) pathway for upregulation of osteoclast cell fusion.

  3. Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma

  4. Inhibition of NMMHC IIA impedes TF expression and venous thrombosis via Akt (show AKT1 Antibodies)/GSK3beta (show GSK3b Antibodies)-NF-kappaB (show NFKB1 Antibodies) signalling pathways in the endothelium both in vitro and in vivo.

  5. Myh9 mediates colitis-induced epithelium injury by restricting Lgr5 (show LGR5 Antibodies)+ stem cells

  6. Mst1 (show MST1 Antibodies) regulates Myosin IIa dynamics to organize high and low affinity LFA-1 (show ITGAL Antibodies) to the anterior and posterior membrane during T cell migration.

  7. DDR1 malfunction causes outer hair cells deformation and the separation of the lateral wall, the location of the cellular motor responsible for the electromotile property, explicitly in those regions showing DDR1 and NM-IIA co-localization.

  8. A new role for Arl13b (show ARL13B Antibodies) in actin cytoskeleton remodeling through the interaction with Myh9.

  9. Lgl1 (show Klra7 Antibodies) forms two distinct complexes in vivo, Lgl1 (show Klra7 Antibodies)-NMIIA and Lgl1 (show Klra7 Antibodies)-Par6alpha (show PARD6A Antibodies)-aPKCzeta (show PRKCZ Antibodies), and that the formation of these complexes is affected by the phosphorylation state of Lgl1 (show Klra7 Antibodies).

  10. While MyoIIA activity is required for F-actin localization at the plasma membrane, it alone is insufficient to localize F-actin to the plasma membrane.

Zebrafish Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) interaction partners

  1. Results demonstrate an important role of NMHC-IIA for the proper formation and function of the glomerulus in zebrafish.

Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) Antigen Profile

Antigen Summary

This gene encodes a conventional non-muscle myosin\; this protein should not be confused with the unconventional myosin-9a or 9b (MYO9A or MYO9B). The encoded protein is a myosin IIA heavy chain that contains an IQ domain and a myosin head-like domain which is involved in several important functions, including cytokinesis, cell motility and maintenance of cell shape. Defects in this gene have been associated with non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness.

Alternative names and synonyms associated with Non-Muscle Myosin Heavy Polypeptide 9 (MYH9)

  • myosin, heavy chain 9, non-muscle (MYH9) antibody
  • myosin, heavy chain 9, non-muscle (Myh9) antibody
  • myosin, heavy chain 9, non-muscle (myh9) antibody
  • myosin, heavy polypeptide 9, non-muscle (Myh9) antibody
  • myosin, heavy polypeptide 9a, non-muscle (myh9a) antibody
  • BDPLT6 antibody
  • C80049 antibody
  • D0Jmb2 antibody
  • dfna17 antibody
  • E030044M24Rik antibody
  • epsts antibody
  • fi22c04 antibody
  • Fltn antibody
  • ftns antibody
  • KLG/PTK7 antibody
  • MHA antibody
  • myh9 antibody
  • myh9l2 antibody
  • Myhn-1 antibody
  • Myhn1 antibody
  • myosin antibody
  • nmhc-ii-a antibody
  • NMHC II-A antibody
  • NMHCIIA antibody
  • NMMHC antibody
  • NMMHC-A antibody
  • NMMHC-IIA antibody
  • nmmhca antibody
  • NMMHC II-a antibody
  • non-muscle antibody
  • nonmuscle antibody
  • TU72.6 antibody
  • wu:fi22c04 antibody
  • wu:fj85e11 antibody
  • zgc:66164 antibody
  • zgc:162029 antibody

Protein level used designations for MYH9

cellular myosin heavy chain, type A , myosin heavy chain 9 , myosin heavy chain, non-muscle IIa , myosin-9 , non-muscle myosin heavy chain A , non-muscle myosin heavy chain IIa , non-muscle myosin heavy polypeptide 9 , nonmuscle myosin heavy chain II-A , NMMHC II-a , NMMHC-IIA , myosin, heavy polypeptide 9, non-muscle , NMMHC-A , nonmuscle myosin heavy chain-A , heavy polypeptide 9 , myosin heavy chain, nonmuscle , non-muscle IIa , type A , nonmuscle myosin II heavy chain A , flectin , myosin IIA , myosin heavy chain IX , fj85e11 , myosin, heavy chain 9, non-muscle, like-2 , zNMHC-IIA

4627 Homo sapiens
481280 Canis lupus familiaris
25745 Rattus norvegicus
396469 Gallus gallus
398083 Xenopus laevis
404108 Bos taurus
100718592 Cavia porcellus
17886 Mus musculus
333938 Danio rerio
Selected quality suppliers for anti-Non-Muscle Myosin Heavy Polypeptide 9 (MYH9) Antibodies
Did you look for something else?